Recent Updates
Recently added Catalysts
DYN

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: Dyne Therapeutics to Participate in Upcoming Investor Conferences
Price reaction · baseline $18.37 (2026-05-12 close) · hit after-hours · clean, no other DYN news in the window
day 0 close · peak
+0.4%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
13%
average across 7 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Zeleciment Rostudirsen
Phase 3 · Duchenne Muscular Dystrophy (DMD)

Full Press Release Details

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) --Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
• 2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY
• 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY
• Goldman Sachs 47thAnnual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL
A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website athttps://investors.dyne-tx.com/news-and-events/events-and-presentationsand a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more athttps://www.dyne-tx.com/, and follow us onX,LinkedInandFacebook.
Last updated: May 13, 2026